Terug
15
14
Dagbereik
€ 7,94
€ 42,00
52-Weeksbereik
€ 7,94
€ 42,00
Volume
3.000
50D / 200D Gem.
€ 42,00
/
€ 42,00
Vorige Slotkoers
€ 42,00
Koershistorie
Financiële Trends
Sectorvergelijking
vs Healthcare sector mediaan (626 peers)
| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 8,8 | 0,4 |
| P/B | 0,9 | 2,9 |
| ROE % | 10,4 | 3,8 |
| Net Margin % | 5,4 | 3,9 |
| Rev Growth 5Y % | 6,9 | 10,0 |
| D/E | 0,0 | 0,2 |
Belangrijkste Punten
Revenue grew 6,91% annually over 5 years — modest growth
Earnings grew 122,22% over the past year
ROE of 10,42% — decent returns on equity
Debt/Equity of 0,00 — conservative balance sheet
Generating 1,39B in free cash flow
P/E of 8,80 — trading at a low valuation
Groei
Revenue Growth (5Y)
6,91%
Revenue (1Y)1,52%
Earnings (1Y)122,22%
FCF Growth (3Y)73,02%
Kwaliteit
Return on Equity
10,42%
ROIC13,68%
Net Margin5,36%
Op. Margin9,51%
Veiligheid
Debt / Equity
0,00
Current Ratio1,04
Interest Coverage0,00
Waardering
P/E Ratio
8,80
P/B Ratio0,91
EV/EBITDA4,14
Dividend Yield0,00%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 1,52% | Revenue Growth (3Y) | 3,83% |
| Earnings Growth (1Y) | 122,22% | Earnings Growth (3Y) | 71,68% |
| Revenue Growth (5Y) | 6,91% | Earnings Growth (5Y) | -6,06% |
| Profitability | |||
| Revenue (TTM) | 10,44B | Net Income (TTM) | 560,00M |
| ROE | 10,42% | ROA | 4,41% |
| Gross Margin | 38,09% | Operating Margin | 9,51% |
| Net Margin | 5,36% | Free Cash Flow (TTM) | 1,39B |
| ROIC | 13,68% | FCF Growth (3Y) | 73,02% |
| Safety | |||
| Debt / Equity | 0,00 | Current Ratio | 1,04 |
| Interest Coverage | 0,00 | Dividend Yield | 0,00% |
| Valuation | |||
| P/E Ratio | 8,80 | P/B Ratio | 0,91 |
| P/S Ratio | 0,47 | PEG Ratio | 0,69 |
| EV/EBITDA | 4,14 | Dividend Yield | 0,00% |
| Market Cap | 4,93B | Enterprise Value | 4,11B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 10,44B | 10,29B | 9,69B | 9,08B | 7,99B |
| Net Income | 560,00M | 252,00M | 190,00M | 480,00M | 719,00M |
| EPS (Diluted) | 4,59 | 2,07 | 1,56 | 3,95 | 6,01 |
| Gross Profit | 3,98B | 3,86B | 3,60B | 3,43B | 2,86B |
| Operating Income | 993,00M | 721,00M | 585,00M | 808,00M | 996,30M |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 12,71B | 13,06B | 12,75B | 13,06B | 10,60B |
| Total Liabilities | 7,26B | 7,75B | 7,79B | 8,09B | 6,30B |
| Shareholders' Equity | 5,44B | 5,31B | 4,96B | 4,97B | 4,29B |
| Total Debt | 0,0 | 5,07B | 5,29B | 5,59B | 4,10B |
| Cash & Equivalents | 813,00M | 331,00M | 272,00M | 376,00M | 345,30M |
| Current Assets | 4,15B | 3,93B | 3,61B | 3,57B | 2,75B |
| Current Liabilities | 3,99B | 3,19B | 4,31B | 4,46B | 4,91B |
Strategiescores
This stock passed the criteria for 2 strategies
Score = fit strength (0–100)
Rank = position among all matches
#752 of 820
#539 of 708
Recente Activiteit
Ingestapt
Deep Value Investing (Seth Klarman)
Mar 24, 2026
Ingestapt
Defensive Investing (Benjamin Graham)
Mar 24, 2026